<?xml version="1.0" encoding="UTF-8"?><abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:dn="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/abstract/scopus_id/85101415220</prism:url><dc:identifier>SCOPUS_ID:85101415220</dc:identifier><eid>2-s2.0-85101415220</eid><pubmed-id>33529769</pubmed-id><pii>S1742706121000714</pii><prism:doi>10.1016/j.actbio.2021.01.043</prism:doi><dc:title>Organophosphate detoxification by membrane-engineered red blood cells</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><citedby-count>3</citedby-count><prism:publicationName>Acta Biomaterialia</prism:publicationName><dc:publisher>Acta Materialia Inc</dc:publisher><source-id>3300147809</source-id><prism:issn>18787568 17427061</prism:issn><prism:volume>124</prism:volume><prism:startingPage>270</prism:startingPage><prism:endingPage>281</prism:endingPage><prism:pageRange>270-281</prism:pageRange><prism:coverDate>2021-04-01</prism:coverDate><openaccess>1</openaccess><openaccessFlag>true</openaccessFlag><dc:creator><author seq="1" auid="57211968736"><ce:initials>P.N.</ce:initials><ce:indexed-name>Smith P.N.</ce:indexed-name><ce:surname>Smith</ce:surname><ce:given-name>Paige N.</ce:given-name><preferred-name><ce:initials>P.N.</ce:initials><ce:indexed-name>Smith P.N.</ce:indexed-name><ce:surname>Smith</ce:surname><ce:given-name>Paige N.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/57211968736</author-url><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/></author></dc:creator><dc:description><abstract xmlns="" original="y" xml:lang="eng"><publishercopyright>Â© 2021</publishercopyright><ce:para>Biotherapeutics have achieved global economic success due to their high specificity towards their drug targets, providing exceptional safety and efficiency. The ongoing shift away from small molecule drugs towards biotherapeutics heightens the need to further improve the pharmacokinetics of these biological drugs. Three pervasive obstacles that limit the therapeutic capacity of biotherapeutics are proteolytic degradation, circulating half-life, and the development of anti-drug antibodies. These challenges can culminate in limited efficiency and consequently warrant the need for higher drug doses and more frequent administration. We have explored the coupling of biotherapeutics to long-lived and biocompatible red blood cells (RBCs) to address limited pharmacokinetics. Butyrylcholinesterase (BChE), for example, provides prophylactic protection against organophosphate nerve agents (OPNAs), yet the short circulation life of the drug requires extraordinary doses. Herein, we report the rapid and tunable chemical engineering of BChE to RBC membranes to create a cell-based delivery system that retains the enzyme activity and enhances stability. In a three-step process that first pre-modifies BChE with a cell-reactive polymer chain, primes the cells for engineering, and then grafts the conjugates to the cells, we attached over 2 million BChE molecules to the surface of each RBC without diminishing the bioscavenging capacity of the enzyme. Critically, this membrane-engineering approach was cell-tolerated with minimal hemolysis observed. These results provide strong evidence for the ability of engineered RBCs to serve as an enhanced biotherapeutic delivery vehicle. Statement of Significance: Organophosphate nerve agents (OPNAs) are one of the most lethal forms of chemical warfare. After exposure to OPNAs, a patient is given life-saving therapeutics, such as atropine and oxime. However, these drugs are limited, and the patient can still suffer from irreparable injuries. Given the toxicity of OPNAs, access to a prophylactic is vital. We have created an enhanced delivery system for prophylactic butyrylcholinesterase (BChE) by engineering this biotherapeutic to the red blood cell (RBC) surface. In three simple steps that first pre-modifies BChE with a cell-reactive polymer, primes the cells for engineering, and then grafts the conjugates to the cells, we attached over 2 million BChE molecules to a single RBC while retaining the enzyme's activity and enhancing its stability.</ce:para></abstract></dc:description><link href="https://api.elsevier.com/content/abstract/scopus_id/85101415220" rel="self"/><link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=85101415220&amp;origin=inward" rel="scopus"/><link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=85101415220&amp;origin=inward" rel="scopus-citedby"/></coredata><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"><affilname>Carnegie Mellon University</affilname><affiliation-city>Pittsburgh</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><authors><author seq="1" auid="57211968736"><ce:initials>P.N.</ce:initials><ce:indexed-name>Smith P.N.</ce:indexed-name><ce:surname>Smith</ce:surname><ce:given-name>Paige N.</ce:given-name><preferred-name><ce:initials>P.N.</ce:initials><ce:indexed-name>Smith P.N.</ce:indexed-name><ce:surname>Smith</ce:surname><ce:given-name>Paige N.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/57211968736</author-url><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/></author><author seq="2" auid="57222085768"><ce:initials>L.</ce:initials><ce:indexed-name>Mao L.</ce:indexed-name><ce:surname>Mao</ce:surname><ce:given-name>Leran</ce:given-name><preferred-name><ce:initials>L.</ce:initials><ce:indexed-name>Mao L.</ce:indexed-name><ce:surname>Mao</ce:surname><ce:given-name>Leran</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/57222085768</author-url><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/></author><author seq="3" auid="7102371027"><ce:initials>K.</ce:initials><ce:indexed-name>Sinha K.</ce:indexed-name><ce:surname>Sinha</ce:surname><ce:given-name>Kaustubh</ce:given-name><preferred-name><ce:initials>K.</ce:initials><ce:indexed-name>Sinha K.</ce:indexed-name><ce:surname>Sinha</ce:surname><ce:given-name>Kaustubh</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7102371027</author-url><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/></author><author seq="4" auid="55257614300"><ce:initials>A.J.</ce:initials><ce:indexed-name>Russell A.J.</ce:indexed-name><ce:surname>Russell</ce:surname><ce:given-name>Alan J.</ce:given-name><preferred-name><ce:initials>A.J.</ce:initials><ce:indexed-name>Russell A.J.</ce:indexed-name><ce:surname>Russell</ce:surname><ce:given-name>Alan J.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/55257614300</author-url><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/></author></authors></abstracts-retrieval-response>